Aurobindo Pharma signs pact with Singapore-based Hilleman Labs for children vaccine

Aurobindo Pharma Limited's wholly-owned subsidiary Auro Vaccines Private Limited on Wednesday informed that it has entered into a licence agreement with Hilleman Laboratories Singapore Pte. Limited.

 

According to the filing, the agreement is about developing, manufacturing and commercializing a pentavalent vaccine candidate used in children vaccination. 

 

Auro Vaccines Private Limited will make milestone payments to Hilleman upon achieving certain development and clinical study outcomes. Hilleman will also be paid royalties upon commercialization of the vaccine candidate, the company said in a statement.

 

Shares of Aurobindo Pharma were under pressure in the morning session due to market volatility and trading at Rs876 per share lower by 0.47% on the BSE today.

Top stories
Company

Delta Corp Q1 PAT Declines 68% YoY to Rs 22 crore in FY25

4 mins read . 13 Jul 2024 . 09:30 AM

Company

Zydus Life Gets USFDA Nod for Heart Failure Drug

3 mins read . 13 Jul 2024 . 09:23 AM

Company

RVNL Spurts 10% on Bagging Multiple Orders Worth Rs 390 Cr

4 mins read . 13 Jul 2024 . 09:18 AM

Related Blogs
blog-logo

Share Market

blog-logo

12 mins read . 12 Jul 2024

Ritesh Agarwal: The OYO Founder’s Success Story

  • 0 people read
blog-logo

Share Market

blog-logo

15 mins read . 08 Jul 2024

Best Oil & Gas Stocks in India

  • 0 people read
Kickstart your equities journey today You've got this
By submitting this I agree to the terms & conditions